Author

John Hackmann

Observed names: Hackmann, John, J Hackmann, J. Hackmann, J.C. Hackmann

Observed institutions: Witten/Herdecke University, University of Cologne, GlaxoSmithKline (United Kingdom), Heidelberg University, University Hospital Heidelberg, Weston Park Cancer Centre, Medizinische Hochschule Hannover, Centre Hospitalier Universitaire de Besançon, Universitätsklinikum Erlangen, Katholisches Klinikum Lünen/Werne , St.-Marien-Hospital Lünen, University Hospital Schleswig-Holstein, Luisenkrankenhaus, GlaxoSmithKline (United States), Hospital Clínic de Barcelona, St. Marien Hospital, Essen University Hospital, City Clinical Oncology Center, Universitäts Frauenklinik, University Hospital Leipzig, Marien Hospital Witten, German Breast Group, Helios Kliniken, Sana Klinikum Offenbach, Women‘s Healthcare Group, Kliniken Essen-Mitte, Rotkreuzklinikum München, University Hospital Cologne, Helios Hospital Berlin-Buch, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Stiftung Charité, Pathologisches Institut, Charité – Universitätsmedizin Berlin, Ludwig-Maximilians-Universität München, Ruhr University Bochum

ORCID: 0000-0002-3787-8955

Observed ORCID: 0000-0002-3787-8955

OpenAlex ID: A5087224341

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

2017 · Miguel Martin, Frankie A Holmes, et al. · The Lancet Oncology · 587

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

2022 · C.E. Geyer, J.E. Garber, et al. · Annals of Oncology · 480

PDF

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial

2016 · Michael Untch, Christian Jackisch, et al. · The Lancet Oncology · 414

NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto

2019 · Michael Untch, Christian Jackisch, et al. · Journal of Clinical Oncology · 157

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

2014 · G. von Minckwitz, G. von Minckwitz, et al. · Annals of Oncology · 137

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

2021 · E.P. Mamounas, M. Untch, et al. · Annals of Oncology · 130

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

2017 · Oleg Gluz, Ulrike Nitz, et al. · JNCI Journal of the National Cancer Institute · 129

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

2016 · S. Loibl, C. Jackisch, et al. · Annals of Oncology · 112

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

2022 · Ulrike Nitz, Oleg Gluz, et al. · The Lancet Oncology · 92

Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials

2021 · Sonia L. Villegas, Valentina Nekljudova, et al. · European Journal of Cancer · 91

Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy

2020 · Joerg Heil, André Pfob, et al. · Annals of Surgery · 64

A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52)

2015 · Gunter von Minckwitz, Bettina Conrad, et al. · Cancer · 60

PDF

RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial

2018 · Joerg Heil, Peter Sinn, et al. · BMC Cancer · 55

PDF

Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer

2021 · R. Charles Coombes, Holly Tovey, et al. · JAMA Oncology · 51

PDF

Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial

2019 · Oleg Gluz, Cornelia Kolberg‐Liedtke, et al. · International Journal of Cancer · 49

De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

2022 · Oleg Gluz, Ulrike Nitz, et al. · Clinical Cancer Research · 39

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

2024 · M. Martín, S.R. Stecklein, et al. · Annals of Oncology · 38

PDF

Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03.

2022 · Joerg Heil, André Pfob, et al. · PubMed · 30

Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)

2017 · Jenny Furlanetto, Christian Jackisch, et al. · Breast Cancer Research and Treatment · 30

Does texture analysis improve breast ultrasound precision?

2000 · W. Bader, S. Böhmer, et al. · Ultrasound in Obstetrics and Gynecology · 28

PDF

Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

2021 · Monika Graeser, Friedrich Feuerhake, et al. · Journal for ImmunoTherapy of Cancer · 27

PDF

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

2022 · Cornelia Kolberg-Liedtke, Friedrich Feuerhake, et al. · Breast Cancer Research · 23

PDF

Abstract S2-07: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69

2015 · Michael Untch, Christian Jackisch, et al. · Cancer Research · 22

Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer

2022 · Jens-Uwe Blohmer, Theresa Link, et al. · JAMA Oncology · 21

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

2013 · U. Nitz, O. Gluz, et al. · Annals of Oncology · 21

Works count: 92

Citation count: 3,025

H-index: 22

I10-index: 30